Dihia Meghnem

Title: Dihia Meghnem: Innovator in the Field of Immunology

Introduction

Dihia Meghnem is a prominent inventor based in Nantes, France. She has made significant contributions to the field of immunology, particularly in the development of therapeutic agents for inflammatory and autoimmune diseases. Her innovative work has led to the creation of a unique polypeptide that targets interleukin-15 (IL-15), a crucial component in immune response regulation.

Latest Patents

Dihia Meghnem holds a patent for a specific interleukin-15 (IL-15) antagonist polypeptide and its uses for the treatment of inflammatory and autoimmune diseases. The patent details a polypeptide that includes an IL15-Ralpha sushi-containing polypeptide with an amino acid sequence that has at least 80% identity with SEQ ID NO:1, a linker, and an IL-polypeptide with an amino acid sequence that has at least 80% identity with SEQ ID NO:4, with a specific mutation at the glutamine (Q) residue at position 108. This invention represents a significant advancement in therapeutic options for patients suffering from these conditions.

Career Highlights

Throughout her career, Dihia Meghnem has worked with esteemed institutions such as the Centre Hospitalier Universitaire de Nantes and the National Institute of Health and Medical Research. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Dihia has collaborated with notable colleagues, including Erwan Mortier and Sebastien Daniel Morisseau. These partnerships have further enhanced her research and development efforts in immunology.

Conclusion

Dihia Meghnem's innovative work in developing IL-15 antagonist polypeptides showcases her dedication to advancing medical science. Her contributions have the potential to significantly impact the treatment of inflammatory and autoimmune diseases, highlighting her role as a leading inventor in the field.